Title	Corynebacterium Parvum [electronic resource] : Applications in Experimental and Clinical Oncology / edited by Bernard Halpern
Imprint	Boston, MA : Springer US, 1975
Connect to	http://dx.doi.org/10.1007/978-1-4613-4428-5
Descript	XIV, 444 p. online resource

In his introduction to the Ciba Foundation Symposium on "Immunopotentiaยญ tion," Sir Peter Medawar stated that, "for the past twenty years the control of the immune response has been virtually equated to immunosuppression because the great goal of applied immunology has been the transplantation of tissues," and that, "with the discovery of tumor immunity-the focal point of immunoยญ logical control has changed from immunosuppression to immunpotentiation and correspondingly the great prize of applied immunology has become the prevenยญ tion and control of malignant growth." Corynebacterium parvum is now univerยญ sally recognized as being the most potent presently known immunopotentiator. C parvum is at the center of almost all papers presented at this conference and it has been analyzed from various viewpoints: taxonomy, pharmacology, immunopotentiation, stimulation of host resistance to tumor invasion in experiยญ mental models and in human therapeutics. Almost all data reported in this volume are original and recently obtained. The discussions were spontaneous, stimulating, and highly enriching, and the results already established and reยญ ported here are in many respects unique. Discussions at the conference revealed many other aspects which require further exploration. Nonspecific immunopotentiation has strongly penetrated into immunology, immunopathology, and, recently, oncology. Undoubtedly, this area of research will witness important developments in the near future. This book offers the first synthesis of presently available knowledge and emphasizes future prospects

I: Bacteriology and Taxonomy -- 1. Bacteriological Aspect of Anaerobic Corynebacteria in Relation to RES Stimulation -- 2. Acute and Chronic Toxicities in Mammal and Subhuman Primates with Inactivated Corynebacterium Suspension -- Discussion -- II: Toxicology, Pharmacology, Adjuvant Properties -- 3. The Nature of the Active Principle of Corynebacterium parvum -- 4. Study on Soluble Substances Extracted from Corynebacterium parvum -- 5. Results Obtained in Our Adjuvant Screening Model with Corynebacterium parvum and Corynebacterium granulosum -- 6. Analysis of the Corynebacterium parvum Adjuvant Effects at the Cellular and Subcellular Levels -- Discussion -- III: Corynebacterium parvum in Microbial Immunity -- 7. Stimulating Effect of Corynebacterium parvum and C. parvum Extract on the Macrophage Activities against Salmonella typhimurium and Listeria monocytogenes -- 8. Antiviral Properties of Corynebacterium parvum -- 9. The Effects of Corynebacterium parvum Suspension on the Response to Tetanus Toxoid -- Discussion -- IV: Action of Corynebacterium parvum on the Immune Cell System -- 10. In Vivo Effects of Lymphocytes Sensitized in Vitro against Tumor Cells -- 11. The Action of Local Injections of Corynebacterium parvum in Facilitating the Extravasation of Activated Lymphoid Cells -- 12. Kinetics of Proliferation of Bone-Marrow Cell Lines after Injections of Immunostimulant Bacteria -- Discussion -- 13. Inhibition of Thymidine Incorporation of Tumoral YC8 Cells Cultured in Vitro by Peritoneal Macrophages Activated with Corynebacterium parvum -- 14. A Comparative, Scanning Electron Microscope Study of the Interaction between Stimulated or Unstimulated Mouse Peritoneal Macrophages and Tumor Cells -- Discussion -- 15. The Macrophage-Stimulating Properties of a Variety of Anaerobic Coryneforms -- 16. Macrophage-Stimulating Effects of Anaerobic Coryneform Bacteria in Vitro -- Discussion -- 17. Comparative Studies on the Effect of Corynebacterium parvum on Bone-Marrow Cell Colony Formation in Vitro -- 18. Nonspecific Cytotoxic Activity of Peritoneal Exudate Cells against Isogenic Tumoral Cells in Animals Treated with Corynebacterium parvum -- Discussion -- V: Corynebacterium parvum in Experimental Tumors and Metastasis -- 19. An Analysis of the Increase in Host Resistance to Isogenic Tumor Invasion in Mice by Treatment with Corynebacterium parvum -- Discussion -- 20. Effect of Inactivated Corynebacterium on Different Experimental Tumors in Mice -- 21. Results of Investigations with Corynebacterium parvum in an Experimental Animal System -- 22. Tumor-Specific Rejection Associated with Killed Corynebacterium parvum -- 23. An Analysis of the Antitumor Effects of Corynebacterium parvum -- Discussion -- 24. Inhibition by Corynebacterium parvum of Lung-Nodule Formation by Intravenously Injected Fibrosarcoma Cells -- 25. Regression of Hamster Melanoma by Corynebacterium parvum -- 26. Corynebacterium granulosum -Induced Prophylaxis and Therapy of Artificial Pulmonary Metastases of Syngenic Murine Tumors -- Discussion -- 27. A Possibility of Synergism between Corynebacterium parvum and Lentinan, Serotonin, or Thyroid Hormone in Potentiation of Host Resistance against Cancer -- 28. Comparative Effects of Various Strains of Corynebacterium parvum and Other Prophylactic Agents on Tumor Development in Animals -- Discussion -- VI: Corynebacterium parvum in Human Tumors -- 29. A Chemotherapeutic Perspective on Clinical Trials with Corynebacterium parvum -- 30. Action of Corynebacterium parvum on the Phagocytic Activity of the Reticuloendothelial System in Cancer Patients (Preliminary Results) -- 31. Corynebacterium parvum: Preliminary Report of a Phase I Clinical and Immunological Study in Cancer Patients -- Discussion -- 32. Results Obtained with Active Immunotherapy using Corynebacteria (Corynebacterium parvum or Corynebacterium granulosum) in the Treatment of Acute Lymphoid Leukemia -- 33. Therapeutic Trial with Reticulostimulin in Patients with Ear, Nose, or Throat Cancers -- 34. The Effect of Intravenous and Intramuscular Injection of Corynebacterium parvum -- 35. Report on 414 Cases of Human Tumors Treated with Corynebacteria -- Discussion -- VII: Concluding Remarks -- 36. Corynebacterium parvum: Outlook and Future -- 37. Closing Remarks -- Contributors -- Discussants

1. Medicine
2. Oncology
3. Medicine & Public Health
4. Oncology